What Is RSO for Cancer and Does It Actually Work?

Rick Simpson Oil, commonly called RSO, is a thick, highly concentrated cannabis extract rich in THC that has been promoted online as a cancer cure since the early 2000s. There is no clinical trial evidence that RSO cures or meaningfully shrinks tumors in humans. Cannabinoids do show genuine anti-cancer activity in lab dishes and animal models, and that research is real and ongoing, but the leap from “kills cancer cells in a petri dish” to “cures cancer in a person” is enormous, and RSO has never made that leap in any rigorous study. Where cannabinoids have earned clearer support is in managing cancer-related symptoms like chemotherapy-induced nausea, and that distinction matters.

What RSO Is and Where It Came From

RSO gets its name from Rick Simpson, a Canadian cannabis activist who claimed in 2003 that he cured his own basal cell carcinoma by applying a homemade, high-THC cannabis oil directly to the skin lesion.¹ He produced the oil by soaking cannabis in a solvent like naphtha or isopropyl alcohol, evaporating the solvent, and collecting the dark, sticky residue. Simpson never submitted his claim to any formal medical scrutiny. Instead, the story spread through word of mouth, YouTube testimonials, and social media, eventually building a global following. Surveys suggest that nearly 40 percent of cancer patients who use cannabis believe it will treat their cancer, with much of that belief fueled by anecdotal reports shared on social platforms.

The oil itself is not standardized. Because it is typically homemade or produced by small, unregulated operations, the THC and CBD concentrations can vary wildly from batch to batch. Hydrocarbon-based extraction methods also pull in plant waxes, particularly long-chain alkanes from the plant’s outer surface, whose abundance depends heavily on extraction temperature.² Residual solvents are another concern in crude preparations. When someone says they are using “RSO,” they could be consuming a product with a very different chemical profile from what another person calls by the same name. This makes it essentially impossible to draw reliable conclusions from user testimonials, because no two people are necessarily taking the same thing.

What Happens When Cannabinoids Meet Cancer Cells in the Lab

The biological story behind RSO’s popularity is not made up out of thin air. Researchers have been studying how cannabinoids interact with cancer cells for decades, and the preclinical findings are genuinely interesting. The human body has an endocannabinoid system with two main receptors, CB1 and CB2, that are activated by most cannabinoids.³ When cannabinoids bind to these receptors on cancer cells, several things have been observed in laboratory settings: tumor cell growth slows, programmed cell death increases, and the formation of new blood vessels that feed tumors is suppressed.⁴

One well-studied mechanism involves a substance called ceramide. When THC is applied to glioma cells (a type of brain cancer), it triggers ceramide to accumulate inside the cells, which sets off a stress response that ultimately causes the cells to self-destruct through a process called autophagy.⁵ CBD appears to work through a related but distinct pathway in pancreatic cancer cells, upregulating a specific enzyme that also leads to cell stress and death.⁶ CBD has also been shown to inhibit angiogenesis, the process by which tumors recruit new blood vessels to sustain their growth, through multiple mechanisms in both cell cultures and animal models.⁷

More recent research has broadened the picture further. Cannabinoids appear capable of triggering not just one type of cell death but several, including apoptosis, autophagy-dependent death, and other recently characterized pathways, across multiple tumor types in the lab.⁸ In a recent animal study using a breast cancer model, mice treated with a THC-CBD extract showed significantly less tumor growth than untreated controls, with tissue analysis confirming reduced cell proliferation and more signs of cell death in the treated tumors.⁹

Why Lab Results Have Not Translated to a Cancer Cure

Every one of those findings is real, peer-reviewed science. The problem is that they describe what happens when you drip cannabinoids directly onto cancer cells in a dish or inject them into a mouse tumor. Hundreds of compounds kill cancer cells in the lab, including household bleach, and that says very little about whether swallowing or applying the substance will produce the same effect in a living human body. In a person, the compound has to survive digestion or first-pass metabolism in the liver, reach the tumor at a sufficient concentration, stay there long enough to act, and do all of this without causing unacceptable harm to healthy tissue. RSO, taken orally or applied to skin, has never been tested in a controlled way that could demonstrate it clears those hurdles.

The human evidence that does exist is thin and mostly limited to isolated case reports or very small pilot studies. One often-cited trial combined a nabiximol oromucosal spray (a pharmaceutical product containing both THC and CBD, not RSO) with temozolomide in glioblastoma patients and reported a one-year survival rate of about 83 percent in the cannabinoid group compared to 44 percent in the placebo group.¹⁰ That sounds dramatic, but it was a small study, the cannabinoid was a standardized pharmaceutical (not a crude homemade extract), and it was used alongside conventional chemotherapy, not as a standalone treatment. An earlier pilot trial that administered THC directly into the brains of patients with recurrent glioblastoma found reduced tumor cell proliferation in only two of nine patients. These are signals worth investigating further, not proof of a cure.

A published case report described a woman with recurrent high-grade serous ovarian cancer who refused additional chemotherapy and instead used a THC/CBD oil. Her tumor marker levels initially dropped, and her disease remained stable for a period of time.¹¹ A single case report, however, cannot establish that cannabis caused the stabilization. Cancers sometimes plateau on their own, and without a control group or larger sample, it is impossible to rule out coincidence. Case reports are useful for generating hypotheses and justifying further research, but they do not constitute evidence that a treatment works.

Where Cannabinoids Actually Help Cancer Patients

The strongest evidence for cannabinoids in oncology is not about shrinking tumors. It is about managing the miserable side effects of cancer and its treatment. Chemotherapy-induced nausea and vomiting is the area with the most data, and the evidence here is genuinely robust.

A systematic review of controlled trials found that cannabinoids were more effective than several older anti-nausea drugs at controlling both nausea and vomiting in chemotherapy patients.¹² A more recent randomized trial tested a standardized oral cannabis extract containing both THC and CBD for chemotherapy-induced nausea and found that the cannabinoid group achieved a complete response rate of 24 percent compared with 8 percent for placebo, with similar improvements across several nausea measures. Side effects included sedation and dizziness but no serious adverse events.¹³ This is the kind of evidence that moves the needle in clinical practice, and it helps explain why synthetic cannabinoids like dronabinol and nabilone have been approved for chemotherapy-related nausea for years.

For chemotherapy-induced nerve damage, a small case series reported that topical cannabinoids provided transient relief of pain and tingling, though the benefit wore off within hours.¹⁴ A separate study found that oral CBD appeared to preserve nerve function in patients receiving certain chemotherapy regimens, with treated patients showing significantly better sensory measurements than controls.¹⁵ These findings are promising but still early-stage.

One area where the popular narrative runs ahead of the evidence is appetite. Many people assume cannabis will reliably boost appetite in cancer patients experiencing weight loss and wasting. The research does not support that assumption. A review of the literature concluded that cannabinoids do not appear to improve appetite, food intake, or weight in cancer patients.¹⁶ A systematic review and meta-analysis of five studies involving over 900 participants found no significant benefit of cannabis-based medicine for appetite, weight change, or quality of life compared to placebo.¹⁷ The “munchies” effect that recreational users experience does not reliably translate to clinically meaningful appetite stimulation in patients who are seriously ill.

Safety Risks You Should Know About

RSO is often framed as a gentle, natural alternative to the harshness of chemotherapy. That framing glosses over real risks, especially at the high doses that RSO protocols typically call for. Most RSO dosing guides circulating online instruct users to ramp up to about a gram of concentrated oil per day, which delivers a very large dose of THC.

One of the less-discussed hazards involves drug interactions with chemotherapy itself. THC is metabolized in the liver through some of the same enzyme pathways that process certain chemo drugs. A detailed pharmacological review outlined how high-dose THC could theoretically impair the effectiveness of irinotecan, a chemotherapy drug used for colorectal and other cancers. The potential interaction points include shared liver enzymes, competition for transport proteins, and possible amplification of liver toxicity.¹⁸ Irinotecan is not the only drug at risk; THC and CBD are both metabolized through common liver enzyme families that overlap with many cancer treatments. A patient who self-medicates with high-dose RSO alongside chemotherapy could be altering how much active drug reaches the tumor, potentially making the chemo less effective or more toxic without knowing it.

Beyond drug interactions, the side effects of high-dose THC itself are not trivial. Sedation, dizziness, anxiety, rapid heart rate, and psychotic episodes can occur, particularly in people who are not regular cannabis users. For patients who are already physically debilitated, these effects can be dangerous in practical terms: a fall from dizziness or sedation in someone weakened by cancer treatment is a serious medical event.

No regulatory agency anywhere in the world has approved cannabinoids for use as a direct cancer treatment. The approvals that exist are limited to symptom management, specifically nausea and vomiting.¹⁹

The Danger of Choosing RSO Instead of Conventional Treatment

The most serious risk of RSO is not a side effect of the oil itself. It is what happens when people use it as a reason to delay or refuse treatments that are known to work. A large study examining cancer patients who chose complementary medicine found that those patients had dramatically higher rates of refusing surgery, chemotherapy, radiotherapy, and hormone therapy compared to patients who did not use complementary approaches. The complementary medicine group had lower five-year survival, and the statistical analysis revealed that the survival difference was driven almost entirely by treatment refusal, not by the complementary medicine causing direct harm.²⁰ Once treatment refusal was accounted for, the independent association with death lost statistical significance.

That finding is worth sitting with. The complementary therapy itself may not have been the killer; the mindset that led patients to skip proven treatments was. RSO communities often cultivate distrust of conventional oncology, framing chemotherapy and radiation as poisons while presenting RSO as a gentle natural cure. When a person with a curable cancer chooses RSO instead of surgery, the oil’s lack of proven anti-tumor effect becomes lethal by omission. This is not a theoretical concern. Oncologists regularly encounter patients who have delayed treatment after finding RSO testimonials online, sometimes arriving months later with cancers that were once operable but no longer are.

What Oncology Guidelines Recommend

The American Society of Clinical Oncology, the largest professional organization of cancer doctors in the United States, published a formal guideline on cannabis and cannabinoids for cancer patients. Its central recommendation is clear: clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment, unless within the context of a clinical trial.²¹ The guideline does acknowledge that cannabis may improve chemotherapy-induced nausea and vomiting that has not responded to standard anti-nausea drugs, which aligns with the trial evidence discussed earlier.

The guideline is not anti-cannabis. It is anti-premature-use. The preclinical data is considered promising enough to justify more clinical trials, and several are underway around the world testing specific cannabinoid formulations in specific cancer types. What the guideline objects to is patients treating themselves with unregulated, unstandardized extracts based on YouTube testimonials and case reports, bypassing the evidence process that exists to separate treatments that help from treatments that merely look promising on paper. If cannabinoids do turn out to have direct anti-tumor effects in humans, the clinical trial pathway is how we will find out, not through thousands of individual experiments conducted in people’s kitchens with inconsistent products and no follow-up data.

Why Testimonials Are So Convincing and So Misleading

If RSO does not have proven anti-cancer effects, why are there so many testimonials from people who say it cured them? Several factors create a perfect environment for false attribution. Many people use RSO alongside conventional treatment, not instead of it. If their tumor shrinks, was it the chemotherapy that worked, the RSO, or both? Without a controlled study, there is no way to know, but the patient and their social circle often credit the RSO. Survivorship bias plays a role too: people whose cancer progressed despite using RSO are less likely to post triumphant YouTube videos. The success stories accumulate online while the failures remain invisible.

Basal cell carcinoma, the cancer Rick Simpson originally claimed to cure, is itself instructive. It is the most common and least dangerous form of skin cancer. It grows very slowly, almost never metastasizes, and in rare cases can even regress on its own. A person who applies any substance to a basal cell carcinoma and watches it apparently improve has not necessarily demonstrated that the substance is an anti-cancer agent. The cancer’s natural behavior can mimic a treatment effect. Simpson’s original claim was never verified by biopsy or independent medical assessment, and basal cell carcinoma is about as far from aggressive metastatic cancer as you can get while still using the word “cancer.”

An analysis of YouTube videos promoting THC for skin cancer found that the platform amplifies dramatic personal narratives while suppressing nuance.¹ Algorithmic recommendation systems favor emotionally compelling content over boring-but-accurate medical information. A tearful video about beating cancer with oil will always outperform a dry explanation of why anecdotal evidence is unreliable. The result is an information environment that systematically makes RSO look more effective than any evidence can support, creating a feedback loop where each new testimonial inspires others to try it and then share their own stories, regardless of whether the oil actually did anything.

Ongoing Research and Clinical Trials

The question of whether cannabinoids could become a legitimate part of cancer treatment is not settled, and serious researchers are still working on it. The preclinical evidence is extensive enough that multiple groups around the world are designing or conducting clinical trials with standardized cannabinoid formulations in specific cancer types.²² The key word there is “standardized.” A crude extract with unknown concentrations of hundreds of compounds is not testable in any meaningful way. Pharmaceutical-grade cannabinoids with consistent dosing are. If a cannabinoid-based cancer treatment is ever validated, it will almost certainly look like a precisely dosed drug, not a syringe of black oil from someone’s kitchen.

Some of the more intriguing research involves combining cannabinoids with existing cancer treatments to see if they can enhance the effect. The glioblastoma trial that paired nabiximols with temozolomide is one example. Others are exploring whether CBD might protect nerves from chemotherapy damage, potentially allowing patients to tolerate longer or more aggressive treatment courses. These combination approaches acknowledge something important: cannabinoids are most likely to help cancer patients not as a replacement for conventional treatment, but as an addition to it, whether for symptom relief, neuroprotection, or possibly future tumor-directed effects that clinical trials have yet to confirm.